Dynavax to Webcast Presentation at Bear Stearns 18th Annual Healthcare Conference
BERKELEY, Calif., Aug 31, 2005 /PRNewswire-FirstCall via COMTEX/ -- Dynavax Technologies (Nasdaq: DVAX) announced today that Dino Dina, MD, President, CEO and Director, will present an overview of the company at the Bear Stearns 18th Annual Healthcare Conference at the Grand Hyatt New York in New York City.
Dr. Dina's presentation will be webcast live at 3:30 pm ET on Tuesday, September 13, 2005. The webcast presentation may be accessed by visiting: http://customer.talkpoint.com/BEAR002/091205a_cy/default.asp?entity=dynavax . The presentation may also be accessed by visiting the Dynavax website at http://www.Dynavax.com under the Investors section where it will also be archived for 30 days following the presentation.
About Dynavax
Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our clinical development programs are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Dynavax's pipeline includes: a ragweed allergy immunotherapeutic, currently in a large-scale Phase 2/3 clinical trial, and in a supportive clinical trial in ragweed allergic children; a hepatitis B vaccine that is currently in a pivotal Phase 3 clinical trial; a cancer therapy currently in a Phase 2 clinical trial; and an asthma immunotherapeutic that has shown preliminary safety and pharmacology in a Phase 2a clinical trial.
SOURCE Dynavax Technologies
Jane M. Green, PhD, Vice President, Corporate Communications of Dynavax Technologies Corporation, +1-510-665-4630, or jgreen@dvax.com
http://www.prnewswire.com